General MedicationsINJECTIONGeneric
RIFAMPIN
RIFAMPIN
Standard Dose
600MG/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview RIFAMPIN is listed in Drugs@FDA under application 206736 (ANDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient RIFAMPIN Form and strength INJECTABLE;INJECTION - 600MG/VIAL Sponsor WATSON PHARMS TEVA Submission history Latest submission status date: 2020-07-06 00:00:00.
Structured Monograph
Clinical summary
Approval overview RIFAMPIN is listed in Drugs@FDA under application 206736 (ANDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient RIFAMPIN Form and strength INJECTABLE;INJECTION - 600MG/VIAL Sponsor WATSON PHARMS TEVA Submission history Latest submission status date: 2020-07-06 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.